Ewing's U: Dr. Christine Heske: New NCI Phase I PEN-866 Clinical Trial

Ewing's U
Written By Alana Arens

Dr. Christine Heske (at NCI) discusses the recently opened PEN-866 (or VTPEN) clinical trial for relapsed and refractory AYA with Ewing or Rhabdomyosarcoma (NCT04890093). We'll discuss the preclinical science behind this trial, key distinguishing features of the newly opened trial, and how patient advocacy and persistence made this trial a reality.

Alana Arens
Previous

Little Warrior Commits $150,000 to MSK to Develop Fusion-Derived Cellular Immunotherapies
Next

Ewing’s U: Dr. Bernadette Brennan: New INTER-EWING-1 Trial (UK / Europe)